Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD
Authors:
Open Access
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 40, 39-45
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary diseaseJournal of Allergy and Clinical Immunology, 2013
- Asthma and coagulationBlood, 2012
- Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and TGF-β/Smad signaling pathwayThrombosis Research, 2011
- Heparin Inhibits Mucus Hypersecretion in Airway Epithelial CellsAmerican Journal of Rhinology & Allergy, 2011
- Mucus hypersecretion in COPD: should we only rely on symptoms?European Respiratory Review, 2010
- Therapeutic implications of the pathophysiology of COPDEuropean Respiratory Journal, 2010
- Heparin and low-molecular-weight heparinThrombosis and Haemostasis, 2008
- Size‐fractionated heparins have differential effects on human neutrophil function in vitroBritish Journal of Pharmacology, 2007
- New Insights into the Inhibition of Human Neutrophil Elastase by HeparinBiochemistry, 2006
- INTRAPULMONARY HEPARIN A New Procedure for Anticoagulant TherapyThe Lancet, 1976